AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Alström Syndrome

Recent research efforts aimed at curing Alström Syndrome.

Last updated

Alström Syndrome

Overview

Alström syndrome is an ultra-rare, autosomal-recessive genetic condition caused by harmful variants in both copies of ALMS1. It is a multisystem “ciliopathy,” meaning that disruption of a protein associated with the cell’s sensory antenna-like primary cilium affects many organs. Symptoms commonly begin in infancy or childhood and include progressive cone-rod retinal degeneration leading to severe visual loss, hearing loss, childhood-onset obesity, marked insulin resistance and type 2 diabetes, cardiomyopathy, and progressive liver and kidney disease. GeneReviews overview

Prognosis varies substantially, including within families, but early cardiomyopathy and later heart, liver, kidney, and metabolic complications can be life-threatening. There is currently no treatment that prevents the syndrome’s progressive organ involvement. Standard care is therefore coordinated, lifelong multidisciplinary management: monitoring and treating heart failure, diabetes, dyslipidemia, liver and kidney disease, alongside hearing and vision support, nutrition and activity adaptations, and psychosocial care. GeneReviews management

Scope of Recent Research (2020–present)

Research since 2020 has been active but remains small because Alström syndrome affects very few people and ALMS1 biology is still incompletely understood. The dominant questions are how ALMS1 loss causes severe metabolic disease, fibrosis, sensory-cell loss, and cardiomyopathy; which complications can be slowed with repurposed metabolic drugs; and how to build models suitable for drug screening and eventual genetic treatment. The community is not yet close to a whole-body cure: current efforts are chiefly disease-mechanism studies and complication-directed treatments, while patient organizations and academic groups are establishing the models, biomarkers, and trial infrastructure needed for future curative programs. ASUK research update

Major Breakthroughs and Emerging Therapies

Metabolic medicines are the most clinically advanced approach, but they are not cures. Setmelanotide, a melanocortin-4 receptor agonist designed to reduce pathological hunger and obesity, was tested in a combined phase 3 trial of Bardet-Biedl syndrome and Alström syndrome. Although the overall study showed meaningful weight and hunger benefits in Bardet-Biedl syndrome, the Alström subgroup did not show statistically significant results; therefore, it has not established an effective disease-modifying treatment for Alström syndrome. Setmelanotide phase 3 trial

A more recent experimental clinical signal comes from tirzepatide, a dual GIP/GLP-1 receptor agonist already used for diabetes and obesity in broader populations. A 2025 report described two people with Alström syndrome treated in routine clinical care: both had weight loss and reduced liver fat, while the magnitude of benefit differed greatly between the two cases. This is encouraging for managing obesity, hyperphagia, insulin resistance, and metabolic dysfunction, but it is uncontrolled evidence from only two patients and does not restore ALMS1 function or reverse established sensory loss. Tirzepatide case report

Mechanistic research has sharpened the therapeutic target from “obesity” to adipose-tissue failure. In a 2021 study, researchers found that ALMS1-deficient human adipocytes and mice develop impaired adipose-tissue function; importantly, genetically reactivating Alms1 specifically in adipose tissue in a conditional mouse model restored systemic insulin sensitivity and glucose tolerance. This is proof-of-principle that correcting ALMS1 activity in a relevant tissue can reverse major metabolic abnormalities in mice, but it used engineered laboratory animals rather than a deliverable human gene therapy. Adipose-tissue reactivation study

A 2024 follow-up study localized much of the metabolic problem to mesenchymal and preadipocyte lineages, the cells that give rise to fat tissue. Selective Alms1 deletion in these cells reproduced insulin resistance, dyslipidemia, and fatty liver in mice, supporting strategies that reduce excess energy balance, improve adipose function, or prevent harmful lipid spillover into organs such as the liver. The same work found little evidence that fibrosis or cellular senescence alone explains the metabolic phenotype in its mouse models, cautioning against assuming that anti-fibrotic or senolytic drugs will be sufficient by themselves. Mesenchymal knockout study

Gene therapy, editing, RNA therapy, and cell therapy remain preclinical aspirations rather than active Alström treatments. ALMS1 is unusually large, making conventional single-vector gene replacement difficult; current UK research planning explicitly identifies the gene’s size as a major obstacle. Current model-building initiatives include patient-derived cell studies, retinal and sensory-loss research, and animal-model work intended to enable future drug screens and genetic-therapy testing. ASUK research update

Clinical Trials and Experimental Approaches

The principal recent interventional evidence is the completed phase 3 setmelanotide trial, NCT03746522, sponsored by Rhythm Pharmaceuticals. It enrolled 38 people with Bardet-Biedl syndrome or Alström syndrome across North America and Europe, followed a 14-week randomized placebo-controlled period with open-label treatment, and found that the primary weight-loss endpoint was achieved only by participants with Bardet-Biedl syndrome; the Alström results were not statistically significant. Skin hyperpigmentation was the most frequent adverse event in the combined study population. Setmelanotide phase 3 trial

An earlier phase 2 program tested the anti-inflammatory and anti-fibrotic small molecule PBI-4050, later called setogepram, in Alström syndrome. The main open-label study, NCT02739217, enrolled 12 adults at University Hospitals Birmingham and was completed in 2018; no results were posted in the registry. Its follow-on open-label rollover study, NCT03184584, enrolled 10 participants and ended in May 2020 after early termination related to redeployment of site staff during the COVID-19 pandemic. These trials were designed to assess safety and biomarker effects rather than to demonstrate a cure. PBI-4050 phase 2 study PBI-4050 rollover study

Clinical research infrastructure is also expanding. The recruiting French cohort study NCT04461444 follows people with Bardet-Biedl and Alström syndromes to characterize long-term clinical and biological disease history, quality of life, and potential trial endpoints; it is observational/translational research rather than a test of a curative drug. Translational cohort study

Methodologies and Scientific Approaches

Researchers combine genetically engineered mouse models, human primary adipocytes with reduced ALMS1 activity, metabolic phenotyping, tissue imaging, and measures such as glucose-tolerance testing, insulin-clamp studies, liver imaging, lipid profiles, and histology. These platforms have been used to test whether specific cell types drive insulin resistance and fatty liver, and to distinguish primary disease mechanisms from downstream complications such as inflammation or fibrosis. Adipose-tissue reactivation study Mesenchymal knockout study

In parallel, clinicians are developing natural-history cohorts and biomarkers because a future trial needs reliable ways to measure whether a therapy changes disease trajectory. Current UK initiatives include patient-derived cellular models for drug screening, studies of premature cellular senescence, and eye and peripheral-nerve biomarkers for tracking neuropathy and sensory disease. ASUK research update

Leading Institutions and Funding

The University of Birmingham, University Hospitals Birmingham, Birmingham Women’s and Children’s Hospital, Newcastle University, Queen’s University Belfast, the University of Exeter, Moorfields Eye Hospital, Alström Syndrome UK, and Alström Syndrome International are prominent contributors to Alström clinical care, natural-history work, patient engagement, and translational research. Rhythm Pharmaceuticals sponsored the pivotal setmelanotide trial, while Liminal BioSciences sponsored the PBI-4050 studies. Setmelanotide phase 3 trial PBI-4050 phase 2 study

A notable recent investment is the LifeArc Centre for Acceleration of Rare Disease Trials, coordinated across Newcastle, Birmingham, and Queen’s University Belfast. It received £12 million as part of nearly £40 million over five years for four LifeArc rare-disease translational centres. Within this ecosystem, Birmingham is funding five non-clinical PhD studentships, including Alström-focused work on models, drug discovery, and senescence-directed approaches; an Alström-specific drug-screening project supported by Alström Syndrome UK runs from October 2025 through September 2029. LifeArc rare-disease trials centre ASUK research update Birmingham senescence project

Strengths, Limitations, and Challenges

The strongest advance is a clearer causal model for the severe metabolic component of Alström syndrome: defective ALMS1 in adipose-lineage cells appears to limit healthy fat-tissue expansion, promoting insulin resistance and lipid accumulation in other organs. The mouse reactivation experiment is especially important because it shows that restoring ALMS1 in a disease-relevant tissue can reverse metabolic abnormalities. Repurposed incretin-based medicines may also provide meaningful near-term benefit for some people, particularly where hyperphagia, obesity, diabetes, and fatty liver are dominant problems. Adipose-tissue reactivation study Tirzepatide case report

However, major barriers remain. Alström syndrome affects multiple organs, so a treatment that improves metabolic disease may not protect the retina, cochlea, heart, kidneys, or lungs. ALMS1’s large coding sequence complicates conventional gene delivery, existing human trials have been very small, and evidence for newer medicines is often limited to case reports or subgroup analyses. Disease variability, progressive irreversible tissue damage before diagnosis, and the scarcity of validated clinical endpoints further complicate trial design and access to future advanced therapies. GeneReviews overview ASUK research update

Outlook and Future Directions

As of September 8, 2026, Alström syndrome is not near a proven cure, and no ALMS1-directed gene replacement, editing, RNA, or cell therapy has yet been established in human clinical trials. The most credible milestones to watch are confirmation of tirzepatide or other metabolic treatments in larger Alström cohorts; publication of long-term results from prior anti-fibrotic programs; validation of eye, nerve, cardiac, liver, and metabolic biomarkers; progress from patient-derived cells and animal models to reproducible drug-screening hits; and, ultimately, a delivery strategy capable of safely restoring or repairing ALMS1 in the tissues where intervention can still preserve function. ASUK research update Translational cohort study

References

Don't see your disease? Request a report